Literature DB >> 26573391

Bevacizumab treatment of macular edema in CRVO and BRVO: long-term follow-up (BERVOLT study: bevacizumab for RVO long-term follow-up).

Dan Călugăru1, Mihai Călugăru2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26573391     DOI： 10.1007/s00417-015-3219-4

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  10 in total

1.  Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study.

Authors:  Yuichiro Ogura; Johann Roider; Jean-François Korobelnik; Frank G Holz; Christian Simader; Ursula Schmidt-Erfurth; Robert Vitti; Alyson J Berliner; Florian Hiemeyer; Brigitte Stemper; Oliver Zeitz; Rupert Sandbrink
Journal:  Am J Ophthalmol       Date:  2014-07-25       Impact factor: 5.258

2.  Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study.

Authors:  David L J Epstein; Peep V Algvere; Gunvor von Wendt; Stefan Seregard; Anders Kvanta
Journal:  Ophthalmology       Date:  2012-03-17       Impact factor: 12.079

3.  [Results of a survey on the occurrence of neovascular glaucoma after central retinal vein occlusion].

Authors:  M Càlugàru
Journal:  J Fr Ophtalmol       Date:  1987       Impact factor: 0.818

4.  Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study.

Authors:  Peter A Campochiaro; Raafay Sophie; Joel Pearlman; David M Brown; David S Boyer; Jeffrey S Heier; Dennis M Marcus; Leonard Feiner; Arun Patel
Journal:  Ophthalmology       Date:  2013-10-07       Impact factor: 12.079

5.  Intravitreal bevacizumab in acute central/hemicentral retinal vein occlusions: three-year results of a prospective clinical study.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  J Ocul Pharmacol Ther       Date:  2014-10-14       Impact factor: 2.671

6.  Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study.

Authors:  Jeffrey S Heier; W Lloyd Clark; David S Boyer; David M Brown; Robert Vitti; Alyson J Berliner; Husain Kazmi; Yu Ma; Brigitte Stemper; Oliver Zeitz; Rupert Sandbrink; Julia A Haller
Journal:  Ophthalmology       Date:  2014-03-27       Impact factor: 12.079

7.  Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study.

Authors:  Peter A Campochiaro; David M Brown; Carl C Awh; S Young Lee; Sarah Gray; Namrata Saroj; Wendy Yee Murahashi; Roman G Rubio
Journal:  Ophthalmology       Date:  2011-06-29       Impact factor: 12.079

8.  Bevacizumab treatment of macular edema in CRVO and BRVO: long-term follow-up. (BERVOLT study: Bevacizumab for RVO long-term follow-up).

Authors:  Tom Kornhauser; Roy Schwartz; Michaella Goldstein; Meira Neudorfer; Anat Loewenstein; Adiel Barak
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-08-14       Impact factor: 3.117

9.  Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis anti-VEGF (RAVE) trial.

Authors:  David M Brown; Charles C Wykoff; Tien P Wong; Angeline F Mariani; Daniel E Croft; Karri L Schuetzle
Journal:  Retina       Date:  2014-09       Impact factor: 4.256

10.  Normal macular thickness measurements in healthy eyes using Stratus optical coherence tomography.

Authors:  Annie Chan; Jay S Duker; Tony H Ko; James G Fujimoto; Joel S Schuman
Journal:  Arch Ophthalmol       Date:  2006-02
  10 in total
  1 in total

Review 1.  Bevacizumab in the treatment of acute central/hemicentral retinal vein occlusions.

Authors:  Dan Călugăru; Mihai Călugăru; Ștefan Țălu
Journal:  Rom J Ophthalmol       Date:  2016 Jul-Sep
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.